The Mayo Clinic Cancer Center (MCCC) Administration (CCA) supports the Director, Senior Leaders, Program Leaders, Shared Resource Directors, and members in advancing MCCC's mission through administrative management, centralized services and overall planning and evaluation. CCA has been led by the Deputy Director for Administration, Jane Welter, MBA, since 2014. She is supported by 3 site-specific Associate Directors: Benjamin Ziemer, MEd, at Mayo Clinic in Florida; Jenny Ho, MPH, MHSA, at Mayo Clinic in Arizona; and David Moertel, MBA, at Mayo Clinic in Rochester, MN. The CCA provides administrative support for all internal and external planning and evaluation efforts, including meetings of the Executive Committee, Research Committee, Clinical Research Committee, Internal Scientific Advisory Committee and the External Advisory Committee. As a matrix center, the CCA coordinates key staff involved with the CCSG and its ancillary activities. This includes 1) Financial administration, including oversight of grant, internal, and philanthropic funds; 2) Grants administration; 3) Management of internal and external collaborations; 4) Shared Resource oversight; 5) Clinical research support; 6) Communications; 7) Informatics; and 8) Space management. In the past funding period, CCA has assisted the Director and Senior Leaders in many efforts including the effort to update the MCCC strategic plan; revision of MCCC membership criteria; and orientation of 5 new Senior Leaders, 13 new Program Leaders, 4 new Shared Resource Directors and 3 new Associate Directors for Administration. CCA works with the Director to manage all MCCC funds, regardless of source, and provide financial oversight for activities such as Developmental Funds and Shared Resources. CCA has partnered with the Department of Development to obtain and manage philanthropic funds and has facilitated scientific collaborations with other Mayo Clinic Centers (Center for Clinical and Translational Science, Center for Individualized Medicine, Center for Regenerative Medicine) and with other institutions (University of Minnesota Masonic Cancer Center, University of Illinois Urbana-Champaign, University of Mississippi Medical Center, University of Central Florida, Florida State University, Arizona State University). CCA has been engaged in increasing support for clinical research at MCCC, for example by implementing an Early Cancer Therapeutics Unit, creating the Clinical Research Committee, and better aligning the Disease Groups with clinical trials. Future directions include continued support for the Director and Senior Leadership; strategic planning efforts; efforts to impact cancer disparities in our catchment area; expanding internal and external collaborations; developing a new tool to manage CCSG-related information; the implementation of a new clinical research management system; and the implementation of measurement of outcomes for career development awards.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015083-47
Application #
10113571
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-04-25
Project End
2024-02-29
Budget Start
2021-03-01
Budget End
2022-02-28
Support Year
47
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Langlais, Blake T; Geyer, Holly; Scherber, Robyn et al. (2018) Quality of life and symptom burden among myeloproliferative neoplasm patients: do symptoms impact quality of life? Leuk Lymphoma :1-7
Yang, Ju Dong; Addissie, Benyam D; Mara, Kristin C et al. (2018) GALAD Score for Hepatocellular Carcinoma Detection in Comparison to Liver Ultrasound and Proposal of GALADUS Score. Cancer Epidemiol Biomarkers Prev :
Kurmi, Kiran; Hitosugi, Sadae; Yu, Jia et al. (2018) Tyrosine Phosphorylation of Mitochondrial Creatine Kinase 1 Enhances a Druggable Tumor Energy Shuttle Pathway. Cell Metab 28:833-847.e8
O'Mara, Tracy A; Glubb, Dylan M; Amant, Frederic et al. (2018) Identification of nine new susceptibility loci for endometrial cancer. Nat Commun 9:3166
Wallace, Sumer K; Halverson, Jessica W; Jankowski, Christopher J et al. (2018) Optimizing Blood Transfusion Practices Through Bundled Intervention Implementation in Patients With Gynecologic Cancer Undergoing Laparotomy. Obstet Gynecol 131:891-898
Shrestha, Shikshya; Zhang, Cheng; Jerde, Calvin R et al. (2018) Gene-Specific Variant Classifier (DPYD-Varifier) to Identify Deleterious Alleles of Dihydropyrimidine Dehydrogenase. Clin Pharmacol Ther 104:709-718
Hu, G; Dasari, S; Asmann, Y W et al. (2018) Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma. Leukemia 32:565-569
Geller, James I; Fox, Elizabeth; Turpin, Brian K et al. (2018) A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase 1 and pilot consortium trial (ADVL1315). Cancer 124:4548-4555
Luchtel, Rebecca A; Dasari, Surendra; Oishi, Naoki et al. (2018) Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements. Blood 132:1386-1398
Oishi, Naoki; Brody, Garry S; Ketterling, Rhett P et al. (2018) Genetic subtyping of breast implant-associated anaplastic large cell lymphoma. Blood 132:544-547

Showing the most recent 10 out of 1129 publications